Skip to main content
Terug
WXIBF logo

WuXi Biologics (Cayman) Inc.

Datakwaliteit: 100%
WXIBF
OTC Healthcare Biotechnology
€ 4,60
€ 0,00 (0,00%)
Marktkapitalisatie: 18,99B
Ook genoteerd als WXXWY OTC
Dagbereik
€ 4,60 € 5,26
52-Weeksbereik
€ 2,26 € 5,61
Volume
32.250
50D / 200D Gem.
€ 4,71 / € 4,34
Vorige Slotkoers
€ 4,60

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 5,7 0,4
P/B 0,5 2,9
ROE % 8,2 3,7
Net Margin % 18,0 3,8
Rev Growth 5Y % 35,1 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue grew 35,06% annually over 5 years — strong growth
Net margin of 17,97% shows strong profitability
Debt/Equity of 0,12 — conservative balance sheet
Generating 1,29B in free cash flow
P/E of 5,66 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 25,43%

Groei

Revenue Growth (5Y)
35,06%
Revenue (1Y)9,63%
Earnings (1Y)-1,28%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
8,17%
ROIC7,98%
Net Margin17,97%
Op. Margin26,63%

Veiligheid

Debt / Equity
0,12
Current Ratio2,73
Interest Coverage31,56

Waardering

P/E Ratio
5,66
P/B Ratio0,45
EV/EBITDA3,15
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 9,63% Revenue Growth (3Y) 10,59%
Earnings Growth (1Y) -1,28% Earnings Growth (3Y) -12,87%
Revenue Growth (5Y) 35,06% Earnings Growth (5Y) 18,73%
Profitability
Revenue (TTM) 18,68B Net Income (TTM) 3,36B
ROE 8,17% ROA 5,89%
Gross Margin 40,97% Operating Margin 26,63%
Net Margin 17,97% Free Cash Flow (TTM) 1,29B
ROIC 7,98% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,12 Current Ratio 2,73
Interest Coverage 31,56 Dividend Yield 0,00%
Valuation
P/E Ratio 5,66 P/B Ratio 0,45
P/S Ratio 1,02 PEG Ratio 15,60
EV/EBITDA 3,15 Dividend Yield 0,00%
Market Cap 18,99B Enterprise Value 15,65B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 18,68B 17,03B 15,27B 10,29B 5,61B
Net Income 3,36B 3,40B 4,42B 3,39B 1,69B
EPS (Diluted) 0,78 0,77 1,01 0,77 0,40
Gross Profit 7,65B 6,83B 6,72B 4,83B 2,53B
Operating Income 4,97B 4,45B 4,34B 3,19B 1,50B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 56,98B 56,58B 49,56B 44,03B 28,96B
Total Liabilities 11,50B 12,56B 13,35B 11,33B 8,06B
Shareholders' Equity 41,82B 40,33B 35,05B 32,28B 20,56B
Total Debt 4,94B 4,56B 4,42B 4,30B 3,33B
Cash & Equivalents 8,28B 9,67B 6,40B 9,00B 7,10B
Current Assets 23,57B 21,20B 18,47B 19,53B 14,20B
Current Liabilities 8,62B 7,64B 9,32B 8,26B 4,50B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#218 of 820
55
Value Defensive Investing (Benjamin Graham)
#13 of 708
75

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026